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The exacerbated induction of innate immune responses in airways can abrogate diverse lung infections by a phenomenon known
as stimulated innate resistance (StIR). We recently demonstrated that the enhancement of innate response activation can effi-
ciently impair Bordetella pertussis colonization in a Toll-like receptor 4 (TLR4)-dependent manner. The aim of this work was to
further characterize the effect of lipopolysaccharide (LPS) on StIR and to identify the mechanisms that mediate this process. Our
results showed that bacterial infection was completely abrogated in treated mice when the LPS of B. pertussis (1mg) was added
before (48 h or 24 h), after (24 h), or simultaneously with the B. pertussis challenge (107 CFU). Moreover, we detected that LPS
completely cleared bacterial infection as soon as 2 h posttreatment. This timing suggests that the observed StIR phenomenon
should be mediated by fast-acting antimicrobial mechanisms. Although neutrophil recruitment was already evident at this time
point, depletion assays using an anti-GR1 antibody showed that B. pertussis clearance was achieved even in the absence of neu-
trophils. To evaluate the possible role of free radicals in StIR, we performed animal assays using the antioxidantN-acetyl cys-
teine (NAC), which is known to inactivate oxidant species. NAC administration blocked the B. pertussis clearance induced by
LPS. Nitrite concentrations were also increased in the LPS-treated mice; however, the inhibition of nitric oxide synthetases did
not suppress the LPS-induced bacterial clearance. Taken together, our results show that reactive oxygen species (ROS) play an
essential role in the TLR4-dependent innate clearance of B. pertussis.
Despite high immunization rates in infants and children inmany countries, the respiratory disease named whooping
cough, or pertussis, remains endemic, with epidemics occurring
every 2 to 5 years (1). Although this pattern has persisted since the
prevaccine era (2), the incidence of the disease has been increasing
steadily over the last 2 decades (3–6). Moreover, some countries
and some states in the United States have reported a rise in cases,
leading to numbers of cases similar to those observed in the 1940s
and 1950s, when vaccination was just becoming widespread (4).
In regard to the possible factors that contribute to this epidemio-
logic situation, much attention has been given to waning immu-
nity associated mainly with the introduction of acellular vaccines,
but another factor contributing to these outbreaks may be the
adaptation of the causative agent, Bordetella pertussis, to vaccine
selection pressure, as was proposed for the first time by Mooi et al.
(7–9). In many countries, the genotypes that predominate within
the current bacterial population are ptxP3, prn2, ptxA1, and fim3-
2, which have been described as the major producers of pertussis
toxin, in contrast to the old strains containing ptxP1 (9). More-
over, in some countries, bacteria that do not express the vaccine
antigen pertactin have been isolated (10, 11). It was proposed that
these modifications allow bacteria to subvert the immune re-
sponse induced in the host by vaccination.
While the relevance of these factors in the epidemiologic situ-
ation of pertussis remains a matter of debate and study, the health
system needs to revise and improve the current strategies used to
control the disease. Basic knowledge, such as the mechanism by
which bacterial clearance may be achieved in the host, is expected
to contribute to the development of new strategies to improve the
control of this disease. Recently, a number of studies have de-
scribed the development of novel antimicrobial strategies that tar-
get the host immune response rather than the pathogen (12–14).
These immunotherapeutics target host pathways that either di-
rectly activate effector cells or relieve pathogen-induced suppres-
sion of host killing mechanisms, resulting in the control and elim-
ination of a wide variety of microorganisms (14). For example, a
novel antimicrobial comprising cationic liposome DNA com-
plexes and a crude membrane protein fraction derived from the
attenuated Francisella tularensis strain LVS was described and ef-
fectively controlled in vivo and in vitro infections of the virulent F.
tularensis strain SchuS4 in mice and human cells, respectively
(15). The dramatic control of F. tularensis infection mediated by
this novel antimicrobial was dependent on the stimulation of both
reactive oxygen and nitrogen species (ROS and RNS, respectively)
in vivo and in vitro (15). Ireland et al. (15) also demonstrated that
the combination of such molecules is an effective antimicrobial
agent against three other important bacteria: Burkholderia pseu-
domallei, Yersinia pestis, and Brucella abortus. Thus, the data
presented herein represent an important step toward the develop-
ment of novel, efficacious, broad-spectrum antimicrobial thera-
pies directed against highly pathogenic microbes.
For B. pertussis, we recently found that stimulation of the lung
innate immune response with lipopolysaccharide (LPS) confers a
high level of protection against challenges with high doses of B.
pertussis (16). This protective phenomenon, termed stimulated
innate resistance (StIR), was observed by other researchers for
diverse lung infections, such as influenza A virus, Streptococcus
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pneumoniae, and Aspergillus niger infections (17). Evans et al. (17)
showed that intranasal administration of a Haemophilus influen-
zae bacterial lysate (nontypeable H. influenzae [NTHI] lysate) is
able to block an otherwise deadly challenge with any of these
pathogens. Furthermore, researchers have demonstrated that the
action of the lysate can be mimicked by the use of a combination of
Toll-like receptor 2 (TLR2) and TLR9 agonists (18). In the case of
B. pertussis, the phenomenon of StIR was shown to be TLR4 de-
pendent (16). In fact, this phenomenon was not observed in the
mouse strain C3H/HeJ, which harbors a signaling defect in TLR4
that renders the mice hyporesponsive to LPS. In the present work,
we have characterized this phenomenon in further detail, showing
that pretreatment with the LPS of B. pertussis induces complete
clearance of bacteria from the lungs if LPS is given 24 to 48 h
before bacterial challenge. Similar results were observed both
when the treatment and challenge were performed at the same
time and when the treatment with B. pertussis LPS followed the
challenge with B. pertussis. Consistent with previous findings re-
ported for other pathogens (17, 19), we have shown that bacterial
clearance does not depend on recruited neutrophils. The rapid
bacterial clearance observed as a consequence of B. pertussis LPS
treatment suggests that the StIR event should be mediated by fast-
acting antimicrobial mechanisms. In fact, we demonstrated that
the StIR phenomenon is associated with increased concentrations
of ROS in the lung lining fluid.
These findings not only deepen the knowledge of StIR in B.
pertussis but also provide an alternative mechanism by which B.
pertussis bacteria can be cleared from the lungs; this information
could be exploited to improve disease control.
MATERIALS AND METHODS
Bacterial strain and growth conditions. The B. pertussis strain used in
this study was Tohama I (CIP 8132; Collection of Institut Pasteur,
France). The B. pertussis strain was grown on Bordet-Gengou (BG) agar
plates containing 10% defibrinated sheep blood. For LPS extraction, sub-
cultures were grown in Stainer-Scholte liquid medium for 20 h at 36.5°C
until the optical density at 650 nm reached 1.0 (20).
Lipopolysaccharide extraction. The LPS from B. pertussis was iso-
lated by the hot phenol-water method (21), along with previously de-
scribed modifications (22). The samples of LPS were dialyzed and lyoph-
ilized. Dry weight measures were used to determine the amounts of LPS
obtained. The quality of each sample was checked by SDS-polyacrylamide
gel electrophoresis (SDS-PAGE) (23; data not shown). We also verified
that the effects observed in the experiments described below were due to
LPS and not to nondetectable contaminants by performing animal assays
with a TLR4-deficient mouse strain (C3H/HeJ), as previously described
(16).
Assessment of bacterial clearance. Specific-pathogen-free BALB/C,
C3H/HeN, and C3H/HeJ mice used in these experiments were originally
obtained from Jackson Laboratories (Bar Harbor, ME) or Harlan (The
Netherlands). All of the mice were maintained in the animal care facilities
of the Instituto Biológico Argentino (BIOL SAIC). All of the mouse pro-
cedures were performed in accordance with Argentine regulations. Inocu-
lums (107 CFU/40ml) were prepared, and the mice were inoculated intra-
nasally as previously described (24). For bacterial counting, the mice were
sacrificed by cervical dislocation, and their lungs were removed and ho-
mogenized in 1 ml of sterile phosphate-buffered saline (PBS). The appro-
priate dilutions were plated on BG blood agar plates and counted after 4
days of incubation at 36.5°C to determine the number of CFU per lung. A
minimum of 5 mice per group were used in each of the 4 independent
experiments performed.
The treatment of mice with LPS was performed by intranasal ad-
ministration of 40 ml of PBS containing purified LPS (1mg) 48 h and 24
h prior to, at the same time as, or 24 h after challenge with a suspension of
B. pertussis (107 CFU/40ml). The animals were sacrificed 24 h after the last
treatment, and their lungs were removed aseptically for bacterial counting
as described above.
Neutrophil depletion. Neutrophils were depleted by intraperitoneal
(i.p.) administration of a purified rat monoclonal antibody (RB6-8C5; 2.0
mg/ml) specific for Ly6G/Ly6C (Gr1) or an isotype control antibody
(HB152). The dosing schedule consisted of administration of 400 mg of
the antibody the day before intranasal inoculation with B. pertussis. The
efficacy of the treatment with anti-Gr1 antibody was confirmed by a re-
duction of at least 95% of the neutrophil populations in the blood, spleen,
and lungs.
ROS inhibition. To block the induced enhancement of ROS, mice
were treated with N-acetyl cysteine (NAC; Fluka) by intranasal adminis-
tration (40 ml of NAC; 0.5 mM). NAC was coadministered with LPS (1
mg) 2 h before challenge withB. pertussis (107 CFU/40ml). ROS inhibition
was confirmed by measuring ROS in the bronchoalveolar lavage (BAL)
fluid of the treated mice, as described below.
NOS. To block the in vivo activity of nitric oxide synthetases (NOS),
the mice were treated by the i.p. route with aminoguanidine salt (5 mg/kg
of body weight; Sigma) 2 h before the B. pertussis challenge, as described
above. NOS inhibition was confirmed by measuring the nitrites in the
BAL fluid of the treated mice, as described below.
For all of the treatments described above, the pertinent controls were
included. For each case, bacterial counting was performed as described
above.
BALfluid analysis.The treated and PBS control mice were euthanized
by intraperitoneal pentobarbital injection, and the thoracic cavity was
dissected. To perform the BAL, the trachea was partially cut, and 1 ml of
sterile PBS was flushed into the lungs and then withdrawn. This procedure
was repeated 3 times. The BAL fluid was centrifuged at 6003 g for 15 min,
and the pellet and supernatant were collected for posterior assays. The
resultant cellular sediment was then washed, resuspended, and counted
using a Neubauer chamber to determine the absolute number.
Cells from the BAL fluid were then stained with fluorescent antibodies
for 1 h at 4°C, and flow cytometry analysis was performed using a
FACSCalibur flow cytometer from Becton, Dickinson (NJ). Fluorescein
isothiocyanate (FITC)-, phycoerythrin (PE)-, allophycocyanin (APC)-
and peridinin chlorophyll protein (PerCP)-conjugated monoclonal spe-
cific antibodies for CD11c (clone N418; hamster IgG; eBioscience, San
Diego, CA), Gr1 (clone RB6-8C5; rat IgG2b; eBioscience), CD11b (clone
M1/70.15; rat IgG2b; Caltag Laboratories, CA), Ly6G (clone 1A8; rat
IgG2a; BD Pharmingen), and Ly6C (AL-21; rat IgM; BD Pharmingen)
were used to label the cells.
The BAL fluid supernatants were processed for ROS detection, and the
nitrite concentrations were determined as described below.
ROS determination. The levels of H2O2 were determined using an
Amplex Red hydrogen peroxide/peroxidase assay kit (Invitrogen). Briefly,
for each reaction, 50 ml of BAL fluid supernatant was mixed with 50 ml
Amplex reagent (10 mM Amplex Red reagent stock solution, 10 U/ml
horseradish peroxidase [HRP] stock solution, and 13 reaction buffer)
and incubated at room temperature for 30 min. Fluorescence was mea-
sured in a FLUOstar Optima instrument (BMG Labtech), with an excita-
tion range of 530 to 560 nm and with fluorescence emission detection at
590 nm. The concentration was calculated based on H2O2 standard
curves.
Nitrite/nitrate measurement. To assess the efficacy of NOS, the inhi-
bition of nitrite/nitrate production was evaluated for the BAL fluid super-
natants by a spectrophotometric method according to the technique de-
scribed by Miranda et al., with the modifications proposed by Beda and
Nedospasov (25, 26).
Statistical analysis. Means 6 standard errors (SE) were determined
for all appropriate data. Two-tailed, unpaired Student t tests were used to
determine the statistical significance of differences between groups. The
results were also analyzed by one-way analysis of variance followed by the
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Bonferroni multiple-comparison test to determine significant differences
between groups.
RESULTS
Protection against B. pertussis colonization. We previously
found that profound inflammatory lung responses to LPS abro-
gated B. pertussis colonization in mice (16). The in vitro incuba-
tion of B. pertussis LPS with bacteria showed that LPS did not
affect the viability of the bacteria, confirming that the observed
effect was mediated by the LPS-induced response in the host, not
by direct toxicity of LPS on the bacteria. To further characterize
the observed phenomenon, we evaluated the LPS kinetics of ac-
tion on B. pertussis Tohama phase I (challenge dose, 107 CFU of B.
pertussis) mouse colonization (Fig. 1). To achieve this aim, the
animals were pretreated with purified B. pertussis LPS (1 mg) 48 h
and 24 h before the B. pertussis challenge. Experiments in which B.
pertussis LPS (1 mg) was administered either at the same time as
the challenge doses or 24 h after the challenge were also con-
ducted. The results obtained were compared with those obtained
for mice inoculated withB. pertussisTohama phase I alone. Twen-
ty-four hours after the last treatment, the lungs of the mice were
collected for bacterial counting. Figure 1A shows that while the
number of recovered colonies from the mice treated only with B.
pertussiswas 5.63 1066 1.63 106 CFU/lung, the number of CFU
recovered from any of the mouse groups treated with LPS de-
creased by at least 5 orders of magnitude compared to that of the
mice treated with B. pertussis alone (P, 0.001).
We also evaluated the kinetics of B. pertussis clearance by
counting the numbers of bacteria recovered from the lungs of
mice simultaneously treated with LPS and B. pertussis at different
times posttreatment (2, 6, 24, and 48 h). The results obtained
again showed significant differences between the animals chal-
lenged withB. pertussis alone and the LPS-plus-B. pertussis-treated
group (P , 0.001) (Fig. 1B). Interestingly, the treatment with B.
pertussisLPS resulted in fast and total clearance ofB. pertussis from
the mouse lungs. B. pertussis LPS induced a total reduction in the
FIG 1 (A) Bacterial colonization upon administration with B. pertussis LPS (1 mg) at different times before and after the B. pertussis challenge. (B) Bacterial
clearance at different times postchallenge, induced by LPS coadministered withB. pertussis. In all cases, the nasal challenge of mice was performed with a sublethal
dose (107 CFU/40 ml) of B. pertussis strain Tohama (Bp). The lungs of the infected mice were collected for bacterial counts 24 h after the last treatment (A) or 2,
6, 24, and 48 h after the B. pertussis challenge. The results show the average counts for five mice per group. The results presented are representative of at least four
independent experiments. *, P, 0.001 in the Bonferroni test. ND, not detected.
StIR Event in B. pertussis Infection
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lung pathogen burden even 2 h after treatment, whereas the sham-
treated mice experienced progressive lung infections.
We confirmed that the observed effects were mediated mainly
by LPS by performing similar experiments with a TLR4-defective
mouse strain (C3H/HeJ). In accordance with our previously re-
ported results (16), similar bacterial counts were recovered from
the lungs of the mice simultaneously treated with LPS and B. per-
tussis and those of the mice treated only with B. pertussis (not
shown).
Early bacterial clearance is not associated with neutrophil
recruitment. To identify the cell population that could be in-
volved in the StIR phenomenon observed for B. pertussis, we an-
alyzed leukocyte recruitment to the lungs and airways. Cells from
BAL fluid were sampled at different times (2, 6, and 24 h) after LPS
treatment and analyzed by flow cytometry. An example of the
gating strategy used to select the cell population to be analyzed is
included in Fig. 2A. Figure 2B shows that alveolar macrophages
(AM), defined as CD11c1 CD11b2 Ly6G2 Gr12 cells, were the
predominant cells in the non-LPS-treated animals. After LPS
treatment, we did not observe significant changes in the popula-
tion of alveolar macrophages (data not shown). In contrast, the
neutrophils, characterized as CD11c2CD11b1 Ly6G1Gr11 cells,
were largely recruited into the bronchoalveolar compartments of
the LPS-treated mice (Fig. 2B). The recruitment into the airways
was detected at 2 h, with the presence of approximately 9.53 102
neutrophils/BAL fluid sample (31% of total cells), and the pres-
ence continued to rise to more than 7.9 3 103 neutrophils/BAL
fluid sample at 24 h postinfection (70% of total cells) (Fig. 2B).
This cellular population recruitment was not observed in the non-
infected lungs.
Because neutrophil infiltration could be essential to LPS ac-
tion, we analyzed the impact of the depletion of Gr11 cells on the
onset of B. pertussis infection (Fig. 3). The antibody used depleted
the Ly6G1 neutrophils as well as the proinflammatory monocytes
(Ly6C1) (27). Remarkably, we found that Gr11 cell depletion did
not affect the LPS-induced B. pertussis clearance.
Bacterial clearance is associated with an increased level of
reactive oxygen species. To evaluate the possible role of free rad-
icals in StIR, we inoculated mice intranasally with a suspension of
B. pertussis supplemented with LPS and NAC, an antioxidant used
therapeutically in inflammatory lung diseases. As a control, we
first checked that NAC, LPS, or a combination of both molecules
did not have an effect on bacterial growth. To this end, we incu-
bated a bacterial suspension for 1 h at 37°C with NAC, LPS, or
NAC plus LPS at the same ratio that we used in the in vivo exper-
iments. After the incubation, the bacterial counts were deter-
mined on Bordet-Gengou agar plates. The bacterial counts ob-
tained for all of the treatments analyzed were similar to those of
the untreated bacterial suspension, indicating that direct interac-
tion with NAC or LPS does not affect bacterial viability.
For the animal experiments, NAC was administered either
alone or in combination with LPS 2 h before the B. pertussis treat-
ment. The numbers of CFU recovered from the lungs of the ani-
mals treated with NAC, LPS, and B. pertussis were compared with
those obtained from mice treated with LPS plus B. pertussis, NAC
plus B. pertussis, or B. pertussis alone. The results obtained showed
that NAC was able to block LPS’s action when it was administered
with LPS 2 h before theB. pertussis treatment (Fig. 4). These results
strongly suggest that free radicals are involved in B. pertussis clear-
ance by LPS administration. As an overall indicator of ROS gen-
eration, we evaluated the levels of H2O2 in the BAL fluid by using
Amplex Red, which is converted to highly fluorescent resorufin
upon oxidation (28, 29) (Fig. 5A). It was observed that ROS levels
in the LPS-treated animals (3.70 6 0.33 mM) were increased in
comparison with the values detected in the BAL fluid of naïve
animals (0.4 6 0.04 mM). Moreover, the concentration of H2O2
was suppressed by the addition of NAC (0.57 6 0.02 mM). To
confirm that the observed effect on ROS was mediated mainly by
B. pertussis LPS, similar experiments to those described above
were performed in a TLR4-defective mouse strain (C3H/HeJ).
The parental TLR4-competent mouse strain C3H/HeN was used
as a positive control. Figure 5B shows that ROS levels were in-
creased in the LPS-treated C3H/HeN animals (3.656 0.37mM) in
comparison with the values detected in the BAL fluid of both the
LPS-treated C3H/HeJ animals (1.246 0.87 mM) and naïve C3H/
HeJ animals (0.316 0.05 mM) or naïve C3H/HeN animals (0.376
0.23mM).
The generation of ROS was also evaluated during B. pertussis
infection. In particular, we analyzed the ROS levels 2 h and 24 h
into the infection process. We observed that the ROS levels de-
tected in the infected mice were similar to those of the noninfected
mice: 1.526 0.77mM and 1.396 0.42mM in the infected mice at
2 h and 24 h, respectively, versus 1.236 0.27mM and 0.886 0.13
mM in the noninfected mice at 2 h and 24 h, respectively.
To determine the putative contribution of reactive nitrogen
species (RNS) to the StIR phenomenon, we evaluated the ability to
clear B. pertussis infection by the administration of LPS in mice
treated with aminoguanidine, a general inhibitor of NOS (Fig. 6).
The inhibition of NOS activity by aminoguanidine treatment was
confirmed in the BAL fluid obtained from LPS-treated mice ver-
sus LPS- and NOS inhibitor-treated mice by measuring the pro-
duction of nitrites and nitrates. We observed that in the BAL fluid
extracted from the LPS-treated mice, the level of nitrites was
15.86 0.3mM. In contrast, in the animals treated with aminogua-
nidine plus LPS, the level of nitrites was 6.16 0.1mM (P, 0.001)
(Fig. 6A). Under these conditions, the blocking of NOS did not
affect the ability of the LPS treatment to eliminateB. pertussis from
the airways (P, 0.001) (Fig. 6B).
DISCUSSION
The present study provides insight into the activity of LPS and the
factors that affect the StIR phenomenon observed during B. per-
tussis infection. Interestingly, we found that bacterial infection
was completely abrogated when the LPS of B. pertussis was added
before (48 h or 24 h), after (24 h), or simultaneously with the B.
pertussis challenge (Fig. 1A). Moreover, we observed that the ef-
fectors of bacterial clearance are fast acting, because at 2 h postin-
fection, the bacterial burden was diminished by several orders of
magnitude (Fig. 1B). In the context of StIR, although neutrophils
are recruited at early time points, they are not relevant for B.
pertussis clearance (Fig. 3). These results are in agreement with
those reported by Evans et al., who showed that neutrophil infil-
tration is not required for protection against different pathogens
induced by StIR (17). The studies by Evans et al. provided the first
insight into the cellular effectors of the resistant phenotype in the
lung. Whereas neutrophils, mast cells, and alveolar macrophages
are expendable in NTHI lysate-induced protection, Evans et al.
showed in vitro that respiratory epithelial cells are sufficient to
sense the treatment and to generate an antimicrobial response
(17).
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In the search for other putative fast-acting microbicidal effec-
tors, we tested if StIR against B. pertussis can be blocked by the
antioxidant NAC. Our results indicate that free radicals partici-
pate in the protection against B. pertussis (Fig. 4). In agreement
with these results, we detected a rise in ROS in the bronchoalveolar
lavage fluid after LPS treatment that could be suppressed by the
coadministration of NAC (Fig. 5). The generation of highly toxic
ROS within intracellular compartments such as the phagosome
has been known for decades (30). It is accepted that different ROS
are produced in this compartment by the action of NADPH oxi-
FIG 2 Leukocyte recruitment into the airways after LPS treatment. The cellular populations in the airways were sampled by BAL and analyzed by flow cytometry
at the indicated time points. (A) BAL fluid dot plots representative of PBS-treated mice (nontreated) and LPS-treated mice. The diagram corresponds to BAL
fluid obtained 24 h after treatment. Alveolar macrophages (AM) were defined as CD11c1 CD11b1 Ly6G2 GR12 cells, and neutrophils (PMN) were defined as
CD11c2 CD11b1 Ly6G1 GR11 cells. (B) Quantitative analysis at different times after treatment of BAL fluid PMN obtained from PBS-treated animals
(nontreated) and LPS-treated mice.
StIR Event in B. pertussis Infection
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dase, aiming to inactivate infective microorganisms that may have
been phagocytosed upon cell activation. In recent years, novel
oxidase enzyme members of the DUOX family have been de-
scribed (31). Some members of this family are expressed at high
levels in airway epithelial cells on the apical membrane and are
thought to participate in microbial killing in the extracellular
compartment (32, 33). In fact, DUOX enzymes are proposed to
perform microbicidal activities in the airways, acting in concert
with lactoperoxidase present in mucosal secretions, which is re-
sponsible for the generation of the highly toxic ion OSCN2, using
H2O2 as an oxidant. Membrane-bound DUOX enzymes supply
the H2O2 that allows this microbicidal mechanism to take place
(34). We detected a significant rise in H2O2 in the BAL fluid upon
intranasal LPS delivery in the TLR4-competent mouse strain but
not the TLR4-deficient mouse strain, which indicates the activa-
tion of this mechanism upon TLR4 stimulation. In the nonstimu-
lated animals, the presence of H2O2 in the BAL fluid corresponded
to the basal quantities of this metabolite generated by the mecha-
nisms described above (35).
Although DUOX expression is induced by proinflammatory
cytokines, especially gamma interferon (36), the role of TLR4 li-
gands as triggers of H2O2 production in the airways, as reported
here, has not been studied extensively. Recently, Moller and col-
leagues (37) showed that in healthy human volunteers, the inha-
lation of micrograms of Salmonella LPS triggers a fast airway re-
sponse, with a peak of H2O2 production at 2 h poststimulation.
According to the technique used, the authors concluded that
H2O2 production under these conditions is maximal in the air-
ways, although the alveoli also contribute to the generation of
ROS. The results presented here are in agreement with the cited
report. Although LPS can also trigger inducible NOS activation
and RNS production, we showed that abrogation of NOS activity
by treatment with aminoguanidine does not impair the LPS bac-
tericidal effect. This result indicates that RNS are not major me-
diators of the observed effect.
The general StIR effect described by Evans and coworkers (17,
19) was triggered by a bacterial lysate containing LPS, among
other pathogen-associated molecular patterns (PAMPs). They
FIG 3 Lung bacterial counts in neutrophil-depleted mice. The nasal challenge
of mice was performed with a sublethal dose (107 CFU/40 ml) of B. pertussis
strain Tohama (Bp) coadministered with 1mg of B. pertussis LPS. The lungs of
the infected mice were collected for bacterial counts 24 h after the treatment.
The results show the average counts for five mice per group. The results are
representative of at least four independent experiments. *, P , 0.001 in the
Bonferroni test. ND, not detected.
FIG 4 Bacterial colonization upon treatment with NAC. Mice were treated
with 1 mg of B. pertussis LPS coadministered with NAC 2 h before challenge
withB. pertussis (107 CFU/40ml). The lungs of the infected mice were collected
for bacterial counts 2 h after the challenge. The results show the average counts
for five mice per group. The results are representative of at least four indepen-
dent experiments. *, P, 0.001 in the Bonferroni test.
FIG 5 Quantification of H2O2 in BAL fluid from BALB/c mice (A) and C3H/
HeN and C3H/HeJ mice (B). In all cases, the mice were treated with 1mg of B.
pertussis LPS alone or coadministered with NAC. BAL fluid samples were
collected for H2O2 determination 2 h after treatment. The results show the
average concentrations for five mice per group. *, P, 0.001 in the Bonferroni
test.
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also showed that StIR is MyD88 dependent and can be triggered by
a combination of TLR2 and TLR9 ligands. They did not test the
effect of an MyD88-dependent TLR4 agonist such as LPS, al-
though they tested MPL as a TLR4 agonist. These authors could
not identify the antimicrobial mechanism operating in their sys-
tem, although they showed that it could be produced by the airway
epithelial cells. They found that epithelial cells, but not macro-
phages and dendritic cells, could be stimulated to kill bacteria in
isolation and that this behavior was associated with the cytokine
profiles, which were very similar to those noted in the whole lung
system. The participation of highly reactive metabolites such as
ROS, as proposed here, may also be a central part of this phenom-
enon. In fact, the participation of an ROS-dependent innate
mechanism is crucial in the clearance of B. pertussis bacteria in-
duced by LPS. This mechanism has not previously been described
in the B. pertussis scenario. Like the case for other pathogens, we
expect that the identification of specific clearance pathways for B.
pertussis will aid in the development of novel therapeutics against
this pathogen.
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